Maio, Michele http://orcid.org/0000-0002-0323-6321
Coukos, George http://orcid.org/0000-0001-8813-7367
Ferrone, Soldano http://orcid.org/0000-0003-2900-8834
Fox, Bernard A. http://orcid.org/0000-0002-4452-5947
Fridman, Wolf H. http://orcid.org/0000-0002-1332-0973
Garcia, Patrick L.
Lahn, Michael
Provendier, Olivier
Russo, Vincenzo http://orcid.org/0000-0003-1592-5041
Rüttinger, Dominik
Shalabi, Aiman
Trajanoski, Zlatko http://orcid.org/0000-0002-0636-7351
Viallet, Jean
Wolchok, Jedd D. http://orcid.org/0000-0001-6718-2222
Ibrahim, Ramy
Article History
Received: 3 September 2018
Accepted: 8 December 2018
First Online: 18 December 2018
Compliance with ethical standards
:
: Michel Lahn was an employee of Incyte Biosciences International Sarl, Geneva, Switzerland, at the time of this panel and holds stocks of Incyte. Dominik Reuttinger is an employee of Roche Pharmaceuticals. Patrick L Garcia is an employee of Merck KGaA. Olivier Provendier is an employee of Laboratoires Pierre Fabre. Michele Maio is a consultant/advisory board member for Bristol-Myers Squibb, Incyte, Merck Sharp & Dohme Oncology, Roche, Astex Pharmaceuticals, Amgen, AstraZeneca and Merck Serono. Ramy Ibrahim is an advisory board member for Harpoon, Arcus, Immunovaccine and ImaginAB. Aiman Shalabi was a consultant at the Cancer Research Institute, New York, NY, USA, at the time of this panel. All other authors declare that they have no conflict of interest.